143 related articles for article (PubMed ID: 31257535)
1. Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review).
Di Benedetto P; Ruscitti P; Liakouli V; Del Galdo F; Giacomelli R; Cipriani P
Mol Med Rep; 2019 Aug; 20(2):1488-1498. PubMed ID: 31257535
[TBL] [Abstract][Full Text] [Related]
2. Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy.
Di Benedetto P; Liakouli V; Ruscitti P; Berardicurti O; Carubbi F; Panzera N; Di Bartolomeo S; Guggino G; Ciccia F; Triolo G; Cipriani P; Giacomelli R
Arthritis Res Ther; 2018 Oct; 20(1):223. PubMed ID: 30285896
[TBL] [Abstract][Full Text] [Related]
3. Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis.
Bartis D; Crowley LE; D'Souza VK; Borthwick L; Fisher AJ; Croft AP; Pongrácz JE; Thompson R; Langman G; Buckley CD; Thickett DR
BMC Pulm Med; 2016 Apr; 16(1):51. PubMed ID: 27080864
[TBL] [Abstract][Full Text] [Related]
4. Targeting fibroblast CD248 attenuates CCL17-expressing macrophages and tissue fibrosis.
Pai CH; Lin SR; Liu CH; Pan SY; Hsu H; Chen YT; Yen CT; Yu IS; Wu HL; Lin SL; Lin SW
Sci Rep; 2020 Oct; 10(1):16772. PubMed ID: 33033277
[TBL] [Abstract][Full Text] [Related]
5. Genetic Deletion of the Stromal Cell Marker CD248 (Endosialin) Protects against the Development of Renal Fibrosis.
Smith SW; Croft AP; Morris HL; Naylor AJ; Huso DL; Isacke CM; Savage CO; Buckley CD
Nephron; 2015; 131(4):265-77. PubMed ID: 26633297
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates targeting CD248 inhibits liver fibrosis through specific killing on myofibroblasts.
Liu S; Han D; Xu C; Yang F; Li Y; Zhang K; Zhao X; Zhang J; Lu T; Lu S; Shi C; Zhang R; Yang AG; Zhao A; Qin W; Yang B; Wen W
Mol Med; 2022 Mar; 28(1):37. PubMed ID: 35317721
[TBL] [Abstract][Full Text] [Related]
7. Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface.
Khan KA; Naylor AJ; Khan A; Noy PJ; Mambretti M; Lodhia P; Athwal J; Korzystka A; Buckley CD; Willcox BE; Mohammed F; Bicknell R
Oncogene; 2017 Nov; 36(44):6097-6108. PubMed ID: 28671670
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis.
Sakai N; Nakamura M; Lipson KE; Miyake T; Kamikawa Y; Sagara A; Shinozaki Y; Kitajima S; Toyama T; Hara A; Iwata Y; Shimizu M; Furuichi K; Kaneko S; Tager AM; Wada T
Sci Rep; 2017 Jul; 7(1):5392. PubMed ID: 28710437
[TBL] [Abstract][Full Text] [Related]
9. CD248 facilitates tumor growth via its cytoplasmic domain.
Maia M; DeVriese A; Janssens T; Moons M; Lories RJ; Tavernier J; Conway EM
BMC Cancer; 2011 May; 11():162. PubMed ID: 21549007
[TBL] [Abstract][Full Text] [Related]
10. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature.
Rybinski K; Imtiyaz HZ; Mittica B; Drozdowski B; Fulmer J; Furuuchi K; Fernando S; Henry M; Chao Q; Kline B; Albone E; Wustner J; Lin J; Nicolaides NC; Grasso L; Zhou Y
Oncotarget; 2015 Sep; 6(28):25429-40. PubMed ID: 26327620
[TBL] [Abstract][Full Text] [Related]
11. Endosialin: molecular and functional links to tumor angiogenesis.
Kontsekova S; Polcicova K; Takacova M; Pastorekova S
Neoplasma; 2016; 63(2):183-92. PubMed ID: 26774137
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates targeting CD248
Xu C; Liu S; Yang F; Zhang K; Li Y; Zhao X; Zhang J; Lu T; Lu S; Jiang Y; Qin W; Shi C; Zhang R; Yang AG; Zhao A; Han D; Wen W
FASEB J; 2022 Feb; 36(2):e22102. PubMed ID: 34972243
[TBL] [Abstract][Full Text] [Related]
13. Simultaneously Targeting Myofibroblast Contractility and Extracellular Matrix Cross-Linking as a Therapeutic Concept in Airway Fibrosis.
Lin YC; Sung YK; Jiang X; Peters-Golden M; Nicolls MR
Am J Transplant; 2017 May; 17(5):1229-1241. PubMed ID: 27804215
[TBL] [Abstract][Full Text] [Related]
14. New developments on skin fibrosis - Essential signals emanating from the extracellular matrix for the control of myofibroblasts.
Schulz JN; Plomann M; Sengle G; Gullberg D; Krieg T; Eckes B
Matrix Biol; 2018 Aug; 68-69():522-532. PubMed ID: 29408278
[TBL] [Abstract][Full Text] [Related]
15. CD248 and its cytoplasmic domain: a therapeutic target for arthritis.
Maia M; de Vriese A; Janssens T; Moons M; van Landuyt K; Tavernier J; Lories RJ; Conway EM
Arthritis Rheum; 2010 Dec; 62(12):3595-606. PubMed ID: 20722022
[TBL] [Abstract][Full Text] [Related]
16. Featured Article: TGF-β1 dominates extracellular matrix rigidity for inducing differentiation of human cardiac fibroblasts to myofibroblasts.
Cho N; Razipour SE; McCain ML
Exp Biol Med (Maywood); 2018 Apr; 243(7):601-612. PubMed ID: 29504479
[TBL] [Abstract][Full Text] [Related]
17. GPRC5B promotes collagen production in myofibroblasts.
Takizawa N; Hironaka T; Mae K; Ueno T; Horii Y; Nagasaka A; Nakaya M
Biochem Biophys Res Commun; 2021 Jul; 561():180-186. PubMed ID: 34023784
[TBL] [Abstract][Full Text] [Related]
18. The double-edged role of IL-22 in organ fibrosis.
Chen J; Lodi R; Zhang S; Su Z; Wu Y; Xia L
Immunopharmacol Immunotoxicol; 2020 Oct; 42(5):392-399. PubMed ID: 32689851
[TBL] [Abstract][Full Text] [Related]
19. Kidney pericytes: a novel therapeutic target in interstitial fibrosis.
Smith SW; Schrimpf C; Parekh DJ; Venkatachalam M; Duffield JS
Histol Histopathol; 2012 Dec; 27(12):1503-14. PubMed ID: 23059881
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor-2 regulates human cardiac myofibroblast-mediated extracellular matrix remodeling.
Svystonyuk DA; Ngu JM; Mewhort HE; Lipon BD; Teng G; Guzzardi DG; Malik G; Belke DD; Fedak PW
J Transl Med; 2015 May; 13():147. PubMed ID: 25948488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
